Header image
![](/sites/default/files/styles/page_header_image/public/2023-07/foto_zahlavi_research_1.jpg?itok=p7pBtlZR)
Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab.
Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab.
British Journal of Cancer.
2013,
108(9),
1807-1809,
ISSN: 0007-0920,
PMID: 23612454,